Fudan Universtiy Shanghai Cancer Centre Trials

Fudan Universtiy Shanghai Cancer Centre	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Hu, Chaosu

AK105-304, NCT04974398: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting

296

Canada, US, RoW

Penpulimab, cisplatin/carboplatin, gemcitabine, placebo

Akeso

Nasopharyngeal Carcinoma

02/26

12/26

JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting

864

Europe, Canada, Japan, US, RoW

Dostarlimab, Placebo

GlaxoSmithKline

Neoplasms, Head and Neck

05/28

07/29

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

GP2017-02, NCT03366415: Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Recruiting

420

RoW

gemcitabine and cisplatin (Induction and adjuvant chemotherapy), IMRT, gemcitabine and cisplatin (Induction chemotherapy), IMRT and concurrent cisplatin

Chaosu Hu, Zhejiang Cancer Hospital, Jiangxi Provincial Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Affiliated Hospital of Jiangnan University, Fujian Cancer Hospital

Nasopharyngeal Carcinoma

09/24

12/24

NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting

212

RoW

PD-1 blocking antibody, JS001, GP, IMRT

Sun Yat-sen University

Recurrent Nasopharyngeal Carcinoma

12/25

12/28

NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting

212

RoW

Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT

Sun Yat-sen University

Nasopharyngeal Carcinoma

12/24

12/27

NCT03866967: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Completed

130

RoW

AK105

Akeso, Akeso Tiancheng, Inc

Nasopharyngeal Carcinoma

03/21

03/24

BL-B01D1-204-02, NCT06437522: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting

RoW

BL-B01D1, PD-1 monoclonal antibody

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinoma

06/26

TRANSFORM, NCT04517214: Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Active, not recruiting

100

RoW

Toripalimab, JS001, IMRT to the nasopharynx and neck, RT to the nasopharynx and neck, Gemcitabine and Cisplatin Chemotherapy, GP regimen chemotherapy, Adjuvant chemotherapy with Capecitabine, Xeloda

Fudan University, Fudan University Eye and ENT Hospital, Anhui Provincial Hospital, Sir Run Run Shaw Hospital, Hangzhou Cancer Hospital, Ningbo Medical Center Lihuili Hospital, The First People's Hospital of Changzhou, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital, Southern Medical University, Shenzhen People's Hospital, First Affiliated Hospital of Xi'anJiaotong Univerisity, Guangzhou Panyu Central Hospital, Fujian Cancer Hospital

Nasopharyngeal Carcinoma

12/25

12/26

NPC-PAPRi 1.0, NCT04978012: Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Recruiting

RoW

Fluzoparib and Camrelizumab

Fudan University

Nasopharyngeal Carcinoma, Nasopharyngeal Cancer

12/24

12/25

NCT06857279: A Phase II Clinical Study to Evaluate HLX43 in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

RoW

HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3

Shanghai Henlius Biotech

Carcinoma of Head And/or Neck

10/27

07/28

NCT06006169: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting

186

RoW

BL-B01D1, SI-B003

Sichuan Baili Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinoma

10/25

NCT05628922: Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Recruiting

198

RoW

Toripalimab, JS001, Induction chemotherapy and concurrent chemoradiation

Fudan University

Nasopharyngeal Cancer

07/26

07/27

NCT04158518: De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruiting

N/A

118

RoW

Toxicities reduced treatment, Conventional treatment

Chaosu Hu

Nasopharyngeal Carcinoma

12/22

Ying, Hongmei

NCT05674305: Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Recruiting

366

RoW

Radiotherapy, Cisplatin

Fudan University

Nasopharyngeal Carcinoma

01/25

01/27

NCT05772208: Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Recruiting

459

RoW

Camrelizumab, Nimotuzumab, neoadjuvant chemotherapy and CCRT

Fudan University

Nasopharyngeal Carcinoma

01/25

01/28

Xu, Tingting

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer

08/25

07/26

IChoice-02, NCT04867330: Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC

Recruiting

N/A

RoW

Toxicities reduced treatment arm

Fudan University

Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation

05/21

01/26

Yang, Youqi

NCT04158518: De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruiting

N/A

118

RoW

Toxicities reduced treatment, Conventional treatment

Chaosu Hu

Nasopharyngeal Carcinoma

12/22

Hu, Chao-su

NCT05628922: Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Recruiting

198

RoW

Toripalimab, JS001, Induction chemotherapy and concurrent chemoradiation

Fudan University

Nasopharyngeal Cancer

07/26

07/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Hu, Chaosu

AK105-304, NCT04974398: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting

296

Canada, US, RoW

Penpulimab, cisplatin/carboplatin, gemcitabine, placebo

Akeso

Nasopharyngeal Carcinoma

02/26

12/26

JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting

864

Europe, Canada, Japan, US, RoW

Dostarlimab, Placebo

GlaxoSmithKline

Neoplasms, Head and Neck

05/28

07/29

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

GP2017-02, NCT03366415: Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Recruiting

420

RoW

gemcitabine and cisplatin (Induction and adjuvant chemotherapy), IMRT, gemcitabine and cisplatin (Induction chemotherapy), IMRT and concurrent cisplatin

Chaosu Hu, Zhejiang Cancer Hospital, Jiangxi Provincial Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Affiliated Hospital of Jiangnan University, Fujian Cancer Hospital

Nasopharyngeal Carcinoma

09/24

12/24

NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting

212

RoW

PD-1 blocking antibody, JS001, GP, IMRT

Sun Yat-sen University

Recurrent Nasopharyngeal Carcinoma

12/25

12/28

NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting

212

RoW

Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT

Sun Yat-sen University

Nasopharyngeal Carcinoma

12/24

12/27

NCT03866967: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Completed

130

RoW

AK105

Akeso, Akeso Tiancheng, Inc

Nasopharyngeal Carcinoma

03/21

03/24

BL-B01D1-204-02, NCT06437522: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting

RoW

BL-B01D1, PD-1 monoclonal antibody

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinoma

06/26

TRANSFORM, NCT04517214: Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Active, not recruiting

100

RoW

Toripalimab, JS001, IMRT to the nasopharynx and neck, RT to the nasopharynx and neck, Gemcitabine and Cisplatin Chemotherapy, GP regimen chemotherapy, Adjuvant chemotherapy with Capecitabine, Xeloda

Nasopharyngeal Carcinoma

12/25

12/26

NPC-PAPRi 1.0, NCT04978012: Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Recruiting

RoW

Fluzoparib and Camrelizumab

Fudan University

Nasopharyngeal Carcinoma, Nasopharyngeal Cancer

12/24

12/25

NCT06857279: A Phase II Clinical Study to Evaluate HLX43 in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

RoW

HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3

Shanghai Henlius Biotech

Carcinoma of Head And/or Neck

10/27

07/28

NCT06006169: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting

186

RoW

BL-B01D1, SI-B003

Sichuan Baili Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinoma

10/25

NCT05628922: Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Recruiting

198

RoW

Toripalimab, JS001, Induction chemotherapy and concurrent chemoradiation

Fudan University

Nasopharyngeal Cancer

07/26

07/27

NCT04158518: De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruiting

N/A

118

RoW

Toxicities reduced treatment, Conventional treatment

Chaosu Hu

Nasopharyngeal Carcinoma

12/22

Ying, Hongmei

NCT05674305: Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Recruiting

366

RoW

Radiotherapy, Cisplatin

Fudan University

Nasopharyngeal Carcinoma

01/25

01/27

NCT05772208: Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Recruiting

459

RoW

Camrelizumab, Nimotuzumab, neoadjuvant chemotherapy and CCRT

Fudan University

Nasopharyngeal Carcinoma

01/25

01/28

Xu, Tingting

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

08/25

07/26

IChoice-02, NCT04867330: Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC

Recruiting

N/A

RoW

Toxicities reduced treatment arm

Fudan University

Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation

05/21

01/26

Yang, Youqi

NCT04158518: De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruiting

N/A

118

RoW

Toxicities reduced treatment, Conventional treatment

Chaosu Hu

Nasopharyngeal Carcinoma

12/22

Hu, Chao-su

NCT05628922: Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Recruiting

198

RoW

Toripalimab, JS001, Induction chemotherapy and concurrent chemoradiation

Fudan University

Nasopharyngeal Cancer

07/26

07/27



	Diseases Companies Products Productz Mechanisms of Action Sites